BeOne Secures FDA Nod for TEVIMBRA-Based Regimen in HER2+ GEA…

Event summary

FDA approves TEVIMBRA (tislelizumab) + ZIIHERA (zanidatamab) + chemotherapy for first-line HER2+ GEA treatment.
Approval based on Phase 3 HERIZON-GEA-01 trial showing median OS of 26.4 months vs. 19.2 months in control arm.
TEVIMBRA becomes BeOne’s first approved foundational asset in solid tumors.
Trial involved 914 patients across 30+ countries, demonstrating efficacy across PD-L1 subgroups.

The big picture

BeOne’s FDA approval positions TEVIMBRA as a cornerstone in HER2+ GEA treatment, addressing a critical unmet need where fewer than 40% of patients survive beyond two years. The approval underscores the growing role of combination immunotherapies in oncology, particularly for aggressive tumor types. With TEVIMBRA now approved in over 50 countries, BeOne is expanding its footprint in solid tumors, competing with established players in the space.

What we're watching

Commercial Execution: Whether BeOne can effectively launch and scale this regimen in a competitive HER2+ GEA market.
Pipeline Expansion: How quickly BeOne advances TEVIMBRA into other solid tumor indications.
Regulatory Momentum: The pace at which BeOne secures additional approvals for TEVIMBRA-based combinations globally.